Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI 48 Trial
H Xu, CT Ruff, RP Giugliano, SA Murphy… - Journal of the …, 2016 - Am Heart Assoc
Background We studied the concomitant use of single antiplatelet therapy (SAPT) on the
efficacy and safety of the anti‐Xa agent edoxaban in patients with atrial fibrillation (AF).
Methods and Results ENGAGE AF‐TIMI 48 was a randomized trial that compared 2 dose
regimens of edoxaban with warfarin. We studied both the approved higher‐dose edoxaban
regimen (HDER; 60 mg daily reduced by one half in patients with anticipated increased drug
exposure), as well as a lower‐dose edoxaban regimen (LDER; 30 mg daily, also reduced by …
efficacy and safety of the anti‐Xa agent edoxaban in patients with atrial fibrillation (AF).
Methods and Results ENGAGE AF‐TIMI 48 was a randomized trial that compared 2 dose
regimens of edoxaban with warfarin. We studied both the approved higher‐dose edoxaban
regimen (HDER; 60 mg daily reduced by one half in patients with anticipated increased drug
exposure), as well as a lower‐dose edoxaban regimen (LDER; 30 mg daily, also reduced by …
以上显示的是最相近的搜索结果。 查看全部搜索结果